Mandate

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

October 03, 2025

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.

Hansa Biopharma AB is a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. The company is listed on Nasdaq Stockholm.

Vinge’s team consisted of Dain Hård Nevonen, Joel Magnusson, Louise Nässén, Joacim Malmqvist and Rebecka Björnestedt.

Related

Vinge advises parts of the consortium in connection with the public takeover offer for Cint

The public takeover offer was announced by a consortium consisting of Triton Fund 6, Bolero, Patrick Comer and Brett Schnittlich. The offer values all shares in Cint at approximately SEK 1,989 million. The shares in Cint are listed on Nasdaq Stockholm, Mid Cap.
April 27, 2026

Vinge advises ABG Sundal Collier in connection with Conapto's issue of subsequent senior secured bonds of SEK 500 million

Vinge has advised ABG Sundal Collier as arranger in connection with Conapto Holding AB (publ)'s issue of subsequent senior secured bonds of SEK 500 million under the existing framework of SEK 2 billion.
April 24, 2026

Vinge advises GBL on its acquisition of BUKO Group

Vinge, together with Latham & Watkins, advises Groupe Bruxelles Lambert (“GBL”) (Euronext Brussels: GBLB) on its acquisition of BUKO Group, a leading platform in temporary traffic management, from funds advised by Equistone Partners Europe and the founding family, while management will re-invest alongside GBL. The transaction, which is subject to customary approvals, will entail a EUR 0.5 billion equity investment by GBL.
April 24, 2026